Antiarrhythmic Drug-Induced Internalization of the Atrial-Specific K+ Channel Kv1.5

被引:55
作者
Schumacher, Sarah M. [1 ]
McEwen, Dyke P. [1 ]
Zhang, Lian [1 ]
Arendt, Kristin L. [1 ]
Van Genderen, Kristin M. [1 ]
Martens, Jeffrey R. [1 ]
机构
[1] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA
关键词
potassium channel; trafficking; cardiac; antiarrhythmic; SYNAPTIC VESICLE ENDOCYTOSIS; CARDIAC POTASSIUM CURRENTS; SURFACE EXPRESSION; BINDING-SITE; FIBRILLATION; QUINIDINE; DYNAMIN; BLOCK; MYOCYTES; TRAFFICKING;
D O I
10.1161/CIRCRESAHA.108.192773
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Conventional antiarrhythmic drugs target the ion permeability of channels, but increasing evidence suggests that functional ion channel density can also be modified pharmacologically. Kv1.5 mediates the ultrarapid potassium current (I-Kur) that controls atrial action potential duration. Given the atrial-specific expression of Kv1.5 and its alterations in human atrial fibrillation, significant effort has been made to identify novel channel blockers. In this study, treatment of HL-1 atrial myocytes expressing Kv1.5-GFP with the class I antiarrhythmic agent quinidine resulted in a dose-and temperature-dependent internalization of Kv1.5, concomitant with channel block. This quinidine-induced channel internalization was confirmed in acutely dissociated neonatal myocytes. Channel internalization was subunit-dependent, activity-independent, stereospecific, and blocked by pharmacological disruption of the endocytic machinery. Pore block and channel internalization partially overlap in the structural requirements for drug binding. Surprisingly, quinidine-induced endocytosis was calcium-dependent and therefore unrecognized by previous biophysical studies focused on isolating channel-drug interactions. Importantly, whereas acute quinidine-induced internalization was reversible, chronic treatment led to channel degradation. Together, these data reveal a novel mechanism of antiarrhythmic drug action and highlight the possibility for new agents that selectively modulate the stability of channel protein in the membrane as an approach for treating cardiac arrhythmias. (Circ Res. 2009; 104: 1390-1398.)
引用
收藏
页码:1390 / U284
页数:32
相关论文
共 38 条
[1]
Effects of flecainide and quinidine on Kv4.2 currents:: voltage dependence and role of S6 valines [J].
Caballero, R ;
Pourrier, M ;
Schram, G ;
Delpón, E ;
Tamargo, J ;
Nattel, S .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (08) :1475-1484
[2]
Safety considerations in the pharmacological management of atrial fibrillation [J].
Camm, A. John .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 127 (03) :299-306
[3]
Allosteric effects of permeating cations on gating currents during K+ channel deactivation [J].
Chen, FSP ;
Steele, D ;
Fedida, D .
JOURNAL OF GENERAL PHYSIOLOGY, 1997, 110 (02) :87-100
[4]
Kv1.5 surface expression is modulated by retrograde trafficking of newly endocytosed channels by the dynein motor [J].
Choi, WS ;
Khurana, A ;
Mathur, R ;
Viswanathan, V ;
Steele, DF ;
Fedida, D .
CIRCULATION RESEARCH, 2005, 97 (04) :363-371
[5]
CHANNEL SPECIFICITY IN ANTIARRHYTHMIC DRUG-ACTION - MECHANISM OF POTASSIUM CHANNEL BLOCK AND ITS ROLE IN SUPPRESSING AND AGGRAVATING CARDIAC-ARRHYTHMIAS [J].
COLATSKY, TJ ;
FOLLMER, CH ;
STARMER, CF .
CIRCULATION, 1990, 82 (06) :2235-2242
[7]
Molecular basis for Kv1.5 channel block -: Conservation of drug binding sites among voltage-gated K+ channels [J].
Decher, N ;
Pirard, B ;
Bundis, F ;
Peukert, S ;
Baringhaus, KH ;
Busch, AE ;
Steinmeyer, K ;
Sanguinetti, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (01) :394-400
[8]
Binding site of a novel Kv1.5 blocker: A "foot in the door" against atrial fibrillation [J].
Decher, Niels ;
Kumar, Pradeep ;
Gonzalez, Teresa ;
Pirard, Bernard ;
Sanguinetti, Michael C. .
MOLECULAR PHARMACOLOGY, 2006, 70 (04) :1204-1211
[9]
Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance [J].
Drolet, B ;
Simard, C ;
Mizoue, L ;
Roden, DM .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (08) :2209-2213
[10]
Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents [J].
Drolet, B ;
Simard, C ;
Roden, DM .
CIRCULATION, 2004, 109 (01) :26-29